The immunological aspects of conventional therapy ((chemo)radiation) for the treatment of head and neck squamous cell carcinoma (HNSCC): an exploratory study.

Recruiting

• Conditions: Hoofd-hals plaveiselcelcarcinomen; Head and neck cancer; HPV+ head and neck squamous cell carcinoma (HNSCC)

• Registration Number: NL-OMON40292
• Lead Sponsor: Antoni van Leeuwenhoek Ziekenhuis

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 23 April 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: Not specified
• Target Recruitment: 20

Inclusion Criteria

- Patients should be at least 18 years of age
- Patients should be able and willing to provide informed consent
- Patients should have the clinical diagnosis of HNSCC
- Tumour should be HPV positive
- WHO performance status 0-2
- Patients are scheduled for:
1.Primary external beam radiotherapy (EBRT)
2.Primary EBRT with concurrent chemotherapy (Cisplatin);

Exclusion Criteria

- Any medical condition that may interfere with the study objectives
- Positive test result for HIV or Hepatitis B or C
- Any other active malignancy than cervical cancer.

Study & Design

• Study Type: Observational invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>To monitor the systemic effects of radiotherapy (RT) alone or in combination<br /><br>with concurrent chemotherapy (CRT) (Cisplatin) on the immune response and<br /><br>T-cells over time in patients with head and neck squamous cell carcinoma<br /><br>(HNSCC). T-cell fenotypic changes and T-cell related functional changes will be<br /><br>investigated.</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>- To compare the systemic immunological effect of RT alone to CRT in HNSCC<br /><br>patients.<br /><br>- To determine the optimal timing for future vaccination in HNSCC patients</p><br>